`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`NUVASIVE, INC.
`Petitioner
`
`v.
`
`WARSAW ORTHOPEDIC, INC.
`Patent Owner
`
`
`Patent Number: 8,251,997 B2
`Issue Date: August 28, 2012
`Title: METHOD FOR INSERTING AN ARTIFICIAL
`IMPLANT BETWEEN TWO ADJACENT VERTEBRAE
`ALONG A CORONAL PLANE
`
`____________
`
`Case IPR2013-00206
`Case IPR2013-00208
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PATENT OWNER'S PRESENTATION
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NuVasive, Inc. v. Warsaw Orthopedic, Inc.
`United States Patent and Trademark Office
`Patent Trial and Appeal Board
`Case Nos. IPR2013-00206 and IPR2013-00208
`
`Patent Owner’s Presentation
`U.S. Patent No. 8,251,997
`
`Case Nos.
`IPR2013‐00206 and IPR2013‐00208
`
`June 5, 2014
`
`1
`
`
`
`Overview Of The Claims
`
`• Direct lateral path
`
`• Introduction of three surgical
`instruments in said path, one
`over the next
`
`• Insertion of an implant that
`spans the full or substantially
`the full transverse width of
`adjacent vertebral bodies
`
`’997 patent, Figs. 26 and 30
`Ex. 1002 at 19‐20 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 3, 6‐7, 9, 11, 19 (IPR2013‐00206)
`Paper 29 at 3, 6‐7, 9, 11, 19 (IPR2013‐00208)
`
`2
`
`
`
`“a path having an axis lying in a coronal plane passing
`through a lateral aspect … to the transverse processes”
`
`’997 Patent at 22:47‐23:30
`NUVASIVE 1002 at 32‐33 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 10, 38 (IPR2013‐00206)
`Paper 29 at 7‐8 (IPR2013‐00208)
`
`3
`
`
`
`“a path having an axis lying in a coronal plane passing
`through a lateral aspect … to the transverse processes”
`
`WARSAW 2038 ¶ 55 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 11 (IPR2013‐00206); Paper 29 at 11 (IPR2013‐00208)
`
`4
`
`
`
`“substantially the full transverse width
`of the vertebral bodies”
`
`Claims 1, 9, 17:
`
`’997 Patent at 23:19‐32
`NUVASIVE 1002 at 33 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 11 (IPR2013‐00206); Paper 29 at 8 (IPR2013‐00208)
`
`5
`
`
`
`“substantially the full transverse width
`of the vertebral bodies”
`
`Fig.30
`
`’997 Patent, Fig. 30,
`NUVASIVE 1002 at 20 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 19 (IPR2013‐00206); Paper 29 at 19 (IPR2013‐00208)
`
`’997 Patent at 20:31‐34
`NUVASIVE 1002 at 31 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 5‐6 (IPR2013‐00206)
`Paper 29 at 5‐6 (IPR2013‐00208)
`
`6
`
`
`
`“substantially the full transverse width
`of the vertebral bodies”
`
`’997 Patent at 3:26‐30
`NUVASIVE 1002 at 23 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 45‐46 (IPR2013‐00206)
`Paper 29 at 45‐46 (IPR2013‐00208)
`
`7
`
`
`
`“substantially the full transverse width
`of the vertebral bodies”
`
`’997 Patent at 11:3‐8
`NUVASIVE 1002 at 27 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 46 (IPR2013‐00206)
`Paper 29 at 46 (IPR2013‐00208)
`
`8
`
`
`
`“substantially the full transverse width
`of the vertebral bodies”
`
`* * *
`
`’997 Patent at 21:4‐11
`NUVASIVE 1002 at 32 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 46 (IPR2013‐00206)
`Paper 29 at 46 (IPR2013‐00208)
`
`9
`
`
`
`“substantially the full transverse width
`of the vertebral bodies”
`
`’997 Patent at 21:33‐38
`NUVASIVE 1002 at 32 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 3 (IPR2013‐00206)
`Paper 29 at 46 (IPR2013‐00208)
`
`10
`
`
`
`“substantially the full transverse width
`of the vertebral bodies”
`
`Board Decision to Institute, Paper 17 at 9 (IPR2013‐00206)
`Board Decision to Institute, Paper 16 at 7‐8 (IPR2013‐00208)
`Paper 32 at 4 (IPR2013‐00206); Paper 29 at 4 (IPR2013‐00208)
`
`11
`
`
`
`12
`
`
`
`“full transverse width of the vertebral bodies”
`
`Claim 24:
`
`’997 Patent at 28:1‐11
`NUVASIVE 1002 at 35 (IPR2013‐00206) (IPR2013‐00208)
`Paper 11 at 4 (IPR2013‐00206)
`Paper 11 at 4 (IPR2013‐00208)
`
`13
`
`
`
`14
`
`
`
`“full transverse width of the vertebral bodies”
`
`Dr. McAfee:
`
`McAfee Dep at 42:6‐13
`WARSAW 2039 at 42 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 38 (IPR2013‐00206)
`Paper 29 at 38 (IPR2013‐00208)
`
`15
`
`
`
`“full transverse width of the vertebral bodies”
`
`Dr. McAfee:
`
`McAfee Decl. at ¶31
`NUVASIVE 1029 at 42‐43 (IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 3 (IPR2013‐00206)
`Paper 43 at 5 (IPR2013‐00208)
`
`16
`
`
`
`’770 Patent to Michelson
`
`* * *
`
`’770 Patent, Figs 11, 12A
`NUVASIVE 1033 at 7 (IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 5 (IPR2013‐00206)
`Paper 43 at 4 (IPR2013‐00208)
`
`’770 Patent at 3:57‐4:3
`NUVASIVE 1033 at 13 (IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 5 (IPR2013‐00206)
`Paper 43 at 4 (IPR2013‐00208)
`
`17
`
`
`
`“Elongated portion”
`
`Claims 9, 17, 24:
`
`’997 Patent at 24:29‐40
`NUVASIVE 1002 at 33 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 12 (IPR2013‐00206)
`Paper 29 at 49 (IPR2013‐00208)
`
`18
`
`
`
`“Elongated portion”
`
`Having a length substantially greater
`than its width.
`
`Patent Owner Response, Paper 32 (IPR2013‐00206) at 12‐14
`
`19
`
`
`
`“Elongated portion”
`
`’997 Patent, Fig 7A
`NUVASIVE 1002 at 11 (IPR2013‐00206) (IPR2013‐00208); Paper 32 at 12 (IPR2013‐00206)
`
`Dr. Sachs:
`
`Sachs Decl. WARSAW 2038 at ¶ 60 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 12 (IPR2013‐00206)
`
`20
`
`
`
`“Elongated portion”
`
`Dr. Sachs:
`
`’997 Patent at 33:29‐37
`NUVASIVE 1002
`(IPR2013‐00206) (IPR2013‐00208)
`
`Sachs Decl. WARSAW 2038 at ¶ 61 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 13 (IPR2013‐00206)
`
`21
`
`
`
`“Elongated portion”
`
`’997 Patent, Figs. 1‐2
`NUVASIVE 1002 at 8 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 13 (IPR2013‐00206)
`
`Dr. McAfee:
`
`McAfee Decl.
`NUVASIVE 1001 at ¶ 14 (IPR2013‐00208); Paper 32 at 13 (IPR2013‐00206)
`
`22
`
`
`
`Jacobson ’374
`
`’374 Patent
`NUVASIVE 1004 at 1 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 19 (IPR2013‐00206)
`Paper 29 at 19 (IPR2013‐00208)
`
`23
`
`
`
`Jacobson ’374
`
`To prevent nerve damage, a nerve stimulator of any
`conventional type . . . may be attached or passed down
`into the cannula or trocar to indicate if either
`instrument is hitting one of the spinal nerves or exiting
`nerve branches.
`The stimulator will cause motion in one of the patient's
`legs if it makes nerve contact.
`
`’374 Patent at 6:32‐40
`NUVASIVE 1004 at 11 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 19‐20 (IPR2013‐00206)
`Paper 29 at 19‐20 (IPR2013‐00208)
`
`24
`
`
`
`Jacobson ’374
`
`Dr. McAfee:
`
`McAfee Dep.
`
`McAfee Dep. Tr. at 28:2‐10
`NUVASIVE 1040 at 28 (IPR2013‐00206) (IPR2013‐00208)
`Paper 50 at 2 (IPR2013‐00206); Paper 47 at 2 (IPR2013‐00208)
`
`25
`
`
`
`Jacobson ’374
`
`McAfee Deposition Testimony
`
`McAfee’s Second Declaration
`
`Q. And the nerves within the dural
`sac are spinal nerves, correct?
`
`A. Yes.
`. . .
`Q. At what point does a spinal
`nerve transition into a nerve root?
`
`A. When it exits the spinal cord.
`
`[T]he term “spinal nerves” was not
`limited only to the spinal cord in its
`ordinary use in the early 1980s, but
`instead other surgeons commonly
`considered the spinal nerves to
`include the spinal cord and the major
`roots/bundles thereof, such as the
`“femoral nerve” that is known to
`extend in/along the psoas muscle
`before it divides into subsequent
`nerve branches.
`
`McAfee Dep. Tr. at 28:2‐10
`NUVASIVE 1040 at 28 (IPR2013‐00206) (IPR2013‐00208)
`Paper 50 at 2 (IPR2013‐00206)
`Paper 47 at 2 (IPR2013‐00208)
`
`2nd McAfee Decl.
`NUVASIVE 1029 at ¶ 42 (IPR2013‐00206) (IPR2013‐00208)
`Paper 50 at 2 (IPR2013‐00206)
`Paper 47 at 2 (IPR2013‐00208)
`
`26
`
`
`
`Jacobson ’374
`
`NUVASIVE 1030 at 1 (IPR2013‐00206) (IPR2013‐00208)
`Paper 53 at 8‐11 (IPR2013‐00206); Paper 50 at 8‐11 (IPR2013‐00208)
`
`27
`
`
`
`Jacobson ’374
`
`To prevent nerve damage, a nerve stimulator of
`any conventional type . . . may be attached or
`passed down into the cannula or trocar to indicate
`if either instrument is hitting one of the spinal
`nerves or exiting nerve branches. The stimulator
`will cause motion in one of the patient's legs if it
`makes nerve contact.
`
`’374 Patent at 6:32‐40
`NUVASIVE 1004 at 11 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 19‐20 (IPR2013‐00206)
`Paper 29 at 19‐20 (IPR2013‐00208)
`
`28
`
`
`
`Jacobson ’374
`
`Dr. Sachs
`
`Such a nerve (the exiting major
`motor lumbar root) that would
`cause motion in a patient’s leg
`would be close to the spinal
`column, which further indicates
`that Jacobson is teaching a
`posterolateral approach. Nerves
`that run through the psoas
`muscle, on the other hand, are
`sensory (not motor) nerves.
`
`Sachs Decl.
`WARSAW 2038 ¶ 77 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 20 (IPR2013‐00206)
`Paper 29 at 20 (IPR2013‐00208)
`
`29
`
`
`
`Jacobson ’374
`
`Dr. McAfee:
`
`2nd McAfee Decl.
`NUVASIVE 1029 at ¶ 42 (IPR2013‐00206) (IPR2013‐00208)
`Paper 40 at 5 (IPR2013‐00208)
`
`NUVASIVE 1055 at ¶ 3 (IPR2013‐00206) (IPR2013‐00208)
`Paper 40 at 5 (IPR2013‐00208)
`
`30
`
`
`
`Jacobson ’374
`
`NUVASIVE 1030 at 1 (IPR2013‐00206) (IPR2013‐00208)
`Paper 53 at 8‐11 (IPR2013‐00206); Paper 50 at 8‐11 (IPR2013‐00208)
`
`31
`
`
`
`Jacobson ’374
`
`As shown in Fig. 3, the needle 8 is inserted laterally
`through the patient’s side above the pelvic crest and is
`percutaneously guided to position near the chosen disc
`under fluoroscopic X‐ray. The spinal needle acts as a
`“go‐no‐go” indicator. If the needle cannot be properly
`positioned this indicates that the procedure cannot be
`used with this particular patient.
`
`’374 Patent at 5:27‐34
`NUVASIVE 1004 at 11 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 20‐21(IPR2013‐00206)
`Paper 29 at 20‐21 (IPR2013‐00208)
`
`32
`
`
`
`Jacobson ’374
`
`Dr. Sachs:
`
`According to Jacobson, this
`needle acts as a “go‐no‐go indicator,”
`such that “[i]f the needle cannot be
`properly positioned this indicates
`that the procedure cannot be used
`on this particular patient.” Id. In my
`opinion, a surgeon would not insert
`a spinal needle in a direct lateral
`approach to the lumbar spine
`because doing so would greatly risk
`perforation of a patient’s bowel.
`
`Sachs Decl.
`WARSAW 2038 at ¶ 78 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 47, 51 (IPR2013‐00206)
`Paper 29 at 47, 50‐51 (IPR2013‐00208)
`
`33
`
`
`
`Jacobson ’374
`
`NUVASIVE 1030 (IPR2013‐00206) (IPR2013‐00208)
`Paper 53 at 8‐11 (IPR2013‐00206); Paper 50 at 8‐11 (IPR2013‐00208)
`
`34
`
`
`
`Jacobson ’374
`
`Dr. McAfee:
`• Spinal needle of Jacobson ’374 no different than
`guide pin of ’997 patent
`
`• No evidence of risk of bowel perforation
`
`• Jacobson teaches to perform standard laminectomy
`if bowel obstructs the direct lateral path
`
`2nd McAfee Decl.
`NUVASIVE 1029 at ¶ 43 (IPR2013‐00206) (IPR2013‐00208)
`Paper 40 at 5 (IPR2013‐00208)
`
`35
`
`
`
`Jacobson ’374
`
`’997 Patent:
`
`’997 Patent at 8:44‐51
`NUVASIVE 1002 at 25 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 23 (IPR2013‐00206)
`Paper 29 at 22 (IPR2013‐00208)
`
`36
`
`
`
`Jacobson ’374
`
`’997 Patent:
`
`’997 Patent at 5:60‐63
`NUVASIVE 1002 at 24 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 22, fn. 3 (IPR2013‐00206)
`Paper 29 at 22, fn. 3 (IPR2013‐00208)
`
`37
`
`
`
`Jacobson ’374
`
`Dr. McAfee:
`• Spinal needle of Jacobson ’374 no different than
`guide pin of ’997 patent
`
`• No evidence of risk of bowel perforation
`
`• Jacobson teaches to perform standard laminectomy
`if bowel obstructs the direct lateral path
`
`2nd McAfee Decl.
`NUVASIVE 1029 at ¶ 43 (IPR2013‐00206) (IPR2013‐00208)
`Paper 40 at 5 (IPR2013‐00208)
`
`38
`
`
`
`Jacobson ’374
`
`Dr. Sachs:
`
`Sachs Decl.
`WARSAW 2038 at ¶ 78 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 22 (IPR2013‐00206); Paper 29 at 21 (IPR2013‐00208)
`
`Maneuvering around a patient’s bowel is important because
`bowel perforation releases bowel contents into the abdominal
`cavity, which can cause a severe infection.
`
`Sachs Decl.
`WARSAW 2038 ¶ 81 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 24 (IPR2013‐00206); Paper 29 at 23 (IPR2013‐00208)
`
`39
`
`
`
`Jacobson ’374
`
`NuVasive submits Friedman
`articles on reply:
`
`Dr. Jacobson:
`
`[T]he direct lateral
`procedure shown in Dr.
`Friedman’s papers is my
`direct lateral procedure
`as described in my ’374
`patent.
`
`Jacobson Decl.
`NUVASIVE 1030 ¶ 8 (IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 6 (IPR2013‐00206)
`Paper 40 at 6 (IPR2013‐00208)
`
`40
`
`Ex. 1036
`
`NUVASIVE 1036
`(IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 6 (IPR2013‐00206)
`Paper 40 at 6 (IPR2013‐00208)
`
`NUVASIVE 1037
`(IPR2013‐00206) (IPR2013‐00208)
`
`
`
`Jacobson ’374
`
`Friedman article:
`
`* * *
`
`NUVASIVE 1036 at 4, 8 (IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 6 (IPR2013‐00206)
`Paper 40 at 6 (IPR2013‐00208)
`
`41
`
`
`
`Jacobson ’374
`
`Friedman article:
`
`NUVASIVE 1037 at 1
`(IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 6 (IPR2013‐00206)
`Paper 40 at 6 (IPR2013‐00208)
`
`42
`
`
`
`Jacobson ’374
`
`Dr. Sachs:
`
`[A] common surgical approach at the time placed the
`patient in a lateral decubitus position and then rolled
`the patient gently toward the prone position. This
`shifted the patient’s internal organs slightly anteriorly,
`providing a clearer posterolateral path to the spine.
`
`Sachs Decl.
`WARSAW 2038 at ¶ 76 (IPR2013‐00206) (IPR2013‐00208)
`(emphasis added)
`Paper 32 at 20 (IPR2013‐00206)
`Paper 29 at 20 (IPR2013‐00208)
`
`43
`
`
`
`Jacobson ’374
`
`NuVasive’s reply:
`
`’378 patent to Foley et al.:
`
`Petitioner’s Reply, Paper 43 at 6 (IPR2013‐00206)
`Petitioner’s Reply, Paper 40 at 6 (IPR2013‐00208)
`
`’378 Patent at 2:28‐41; NUVASIVE 1039 at 10 (IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 6 (IPR2013‐00206); Paper 40 at 6 (IPR2013‐00208)
`
`44
`
`
`
`’317 Patent to Kambin
`
`’317 Patent at 2:43‐46
`NUVASIVE 1048 at 5 (IPR2013‐00206) (IPR2013‐00208)
`
`45
`
`
`
`’448 Patent to Kambin
`
`’448 Patent at 5:6‐8
`NUVASIVE 1013 at 6 (IPR2013‐00208)
`
`46
`
`
`
`Jacobson ’374
`
`McAfee First
`Declaration
`One of skill in the art . . .
`would have understood
`that Jacobson’s
`suggested fusion
`procedure would
`necessarily involve the
`implantation of a spinal
`implant.
`
`McAfee’s Deposition
`Testimony
`A spine fusion
`anywhere can be
`with or without an
`implant.
`
`McAfee Decl.
`NUVASIVE 1001 ¶ 28 (IPR2013‐00206)
`NUVASIVE 1001 ¶ 27 (IPR2013‐00208)
`(emphasis added)
`Paper 32 at 25 (IPR2013‐00206)
`Paper 29 at 24 (IPR2013‐00208)
`
`McAfee Dep. Tr. at 26:23‐27:1
`NUVASIVE 1040 at 26‐27 (IPR2013‐
`00206) (IPR2013‐00208)
`Paper 32 at 25 (IPR2013‐00206)
`Paper 29 at 25 (IPR2013‐00208)
`
`47
`
`
`
`McAfee Deposition Testimony
`
`Dr. McAfee:
`
`McAfee Dep at 24:15‐24
`NUVASIVE 1040 at 24 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 26 (IPR2013‐00206); Paper 29 at 25‐26 (IPR2013‐00208)
`
`48
`
`
`
`Brantigan ’327
`
`’327 Patent at 3:51‐52
`NUVASIVE 1006 at 6 (IPR2013‐00206) (IPR2013‐00208)
`Paper 11 at 39, 40 (IPR2013‐00206); Paper 11 at 39, 40 (IPR2013‐00208)
`
`49
`
`
`
`Brantigan ’327
`
`Dr. Brantigan’s 2011 Trial Testimony:
`
`Q. Figure 11 was not inserted translaterally; correct?
`
`A. Yeah, I have a hard time understanding just what that is.
`
`Q. It's your patent?
`
`A. Well, there are details that I have a hard time understanding
`because in figure 10 the insertion tool hole is laterally, and I
`agree with you in this the insertion hole is anterior.
`
`Brantigan Dep at 1516:18‐25
`WARSAW 2041 at 43 (IPR2013‐00206) (IPR2013‐00208)
`Paper 11 at 28 (IPR2013‐00206)
`Paper 11 at 28 (IPR2013‐00208)
`
`50
`
`
`
`Brantigan ’327
`
`Dr. Brantigan’s 2011 Trial Testimony:
`Q: Dr. Brantigan, no doubt in your mind that Figure 11 shows
`your cage being inserted from an anterior to a posterior
`direction; correct?
`
`A: There is doubt in my mind, yes.
`
`Brantigan Dep at 1553:4‐7
`NUVASIVE 1041 at 111 (IPR2013‐00206) (IPR2013‐00208)
`Paper 46 at 1 (IPR2013‐00206)
`Paper 46 at 1 (IPR2013‐00208)
`
`51
`
`
`
`Brantigan ’327
`
`Dr. Brantigan’s
`2011 Trial Testimony:
`
`Dr. Brantigan’s
`Declaration:
`
`Q. So you're now saying that figure 11 shows
`a lateral?
`A. Yes, it does.
`
`****
`Q. Doctor, you asked Mr. Dauchot to allow
`you to explain. So this is your opportunity.
`A. Yes. Thank you. 11 is a plane view through
`the plane [xi‐xi] . . . . So that would be a
`cut through that level. And that would
`mean you're looking at it from the side.
`The discrepancy is that shows transverse
`processes in the vertebral below and
`that's incorrect.
`
`Brantigan Dep at 1553:18‐20, 1556:10‐17
`NUVASIVE 1041 at 111, 114 (IPR2013‐00206) (IPR2013‐00208)
`Paper 46 at 2 (IPR2013‐00206); Paper 46 at 2 (IPR2013‐00208)
`
`“Figure 11 of my '327 patent
`illustrates the lower
`intervertebral space of figure
`10 (prepared for an anterior
`insertion version of my
`implant) . . . .”
`
`NUVASIVE 1031 at ¶16
`(IPR2013‐00206) (IPR2013‐00208)
`Paper 43 at 8 (IPR2013‐00206)
`Paper 40 at 8 (IPR2013‐00208)
`
`52
`
`
`
`Brantigan ’327
`
`’327 Patent at 2:56‐66
`NUVASIVE 1006 at 5 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 30 (IPR2013‐00206)
`Paper 29 at 30 (IPR2013‐00208)
`
`53
`
`
`
`Brantigan ’327
`
`Sachs Decl.
`WARSAW 2038 at ¶ 103 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 30 (IPR2013‐00206)
`Paper 29 at 30 (IPR2013‐00208)
`
`54
`
`
`
`Brantigan ’327
`
`’327 Patent, Fig. 12
`NUVASIVE 1006
`(IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 29 (IPR2013‐00206)
`Paper 29 at 29 (IPR2013‐00208)
`
`55
`
`
`
`Brantigan ’327
`
`Brantigan ’757:
`
`’757 Patent, Figs 3‐4
`WARSAW 2042 at 2
`(IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 31 (IPR2013‐00206)
`Paper 29 at 31 (IPR2013‐00208)
`
`’757 Patent at 4:62‐66
`WARSAW 2042 at 5 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 31 (IPR2013‐00206)
`Paper 29 at 31 (IPR2013‐00208)
`
`56
`
`
`
`Brantigan ’327
`
`Dr. McAfee:
`
`Q. And you are also aware of physicians who use persons
`in the art, skilled in the art and the relevant art here
`who use the term "lateral" to describe something that
`is adjacent to the midline, lateral to the midline of the
`vertebral body, right?
`
`A. Yes.
`
`McAfee Dep. Tr. at 38:20‐39:1
`WARSAW 2039 at 9 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 18 (IPR2013‐00206)
`Paper 29 at 17‐18 (IPR2013‐00208)
`
`57
`
`
`
`Brantigan ’327
`
`Brantigan ’327 patent:
`
`’327 Patent at 1:54‐59
`NUVASIVE 1006 at 5 (IPR2013‐00206) (IPR2013‐00208)
`Ex. 2038 ¶ 110, Paper 32 at 38 (IPR2013‐00206); Ex. 2038 ¶ 110, Paper 29 at 38 (IPR2013‐00208)
`
`’327 Patent at 2:14‐15
`NUVASIVE 1006 at 5 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 38 (IPR2013‐00206)
`Paper 29 at 38 (IPR2013‐00208)
`
`58
`
`
`
`Brantigan ’327
`
`Dr. Sachs:
`
`Sachs Decl.
`WARSAW 2038 at ¶ 110 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 37‐38 (IPR2013‐00206)
`Paper 29 at 37‐38 (IPR2013‐00208)
`
`59
`
`
`
`Brantigan ’327
`
`Dr. Brantigan:
`
`Brantigan Decl.
`NUVASIVE 1031 at ¶20 (IPR2013‐00206) (IPR2013‐00208)
`See Paper 49 at 5, Paper 32 at 38 (IPR2013‐00206); See Paper 46 at 5, Paper 29 at 38 (IPR2013‐00208)
`
`Dr. Brantigan 2011 Trial Testimony:
`
`Brantigan Trial Testimony at 1520:13‐16
`NUVASIVE 1041 at 76, (IPR2013‐00206) (IPR2013‐00208)
`See Paper 49 at 5, Paper 32 at 38 (IPR2013‐00206); See Paper 46 at 5, Paper 29 at 38 (IPR2013‐00208)
`
`60
`
`
`
`Brantigan ’327
`
`Dr. McAfee:
`
`Dr. Brantigan 2011 Trial Testimony:
`
`2nd McAfee Decl.
`NUVASIVE 1029 at ¶73 (IPR2013‐00206) (IPR2013‐00208); Paper
`49 at 4‐5 (IPR2013‐00206); Paper 46 at 4‐5 (IPR2013‐00208)
`
`Brantigan Trial Testimony
`at 1491:2‐7
`NUVASIVE 1041 at 45
`(IPR2013‐00206)
`(IPR2013‐00208);
`Paper 49 at 4‐5 (IPR2013‐
`00206); Paper 46 at 4‐5
`(IPR2013‐00208)
`
`61
`
`
`
`Brantigan ’327
`
`Dr. McAfee:
`Q. Okay so the hard cortical bone is
`part of the end plate and at a
`certain point that becomes
`confluent with the apophyseal
`ring, right?
`A. Correct.
`Q. Okay. And then at some point, as
`you get closer to the edge of the
`vertebra, it's all apophyseal ring?
`A. That's correct.
`
`McAfee Dep at 49:16‐24
`WARSAW 2039 at 18 (IPR2013‐00206) (IPR2013‐00208)
`
`62
`
`Sachs Decl.
`WARSAW 2038 at ¶ 29 (IPR2013‐00206)
`(IPR2013‐00208)
`Paper 32 at 33‐34 (IPR2013‐00206)
`Paper 29 at 33‐34 (IPR2013‐00208)
`
`
`
`Brantigan ’327
`
`Dr. McAfee:
`
`Dr. Brantigan 2011 Trial Testimony:
`
`NUVASIVE 1029 at ¶3 (IPR2013‐00206) (IPR2013‐00208)
`
`2nd McAfee Decl.
`
`Paper 49 at 4 (IPR2013‐00206); Paper 46 at 4 (IPR2013‐00208)
`
`Brantigan Trial Testimony at 1520:6‐10; NUVASIVE 1041 at 76 (IPR2013‐00206) (IPR2013‐00208)
`Paper 49 at 4 (IPR2013‐00206); Paper 46 at 4 (IPR2013‐00208)
`
`63
`
`
`
`Brantigan ’327
`
`Dr. Brantigan’s 2011 Direct Trial Testimony:
`
`Brantigan Trial Testimony at 1495:7‐12
`NUVASIVE 1041 at 49 (IPR2013‐00206) (IPR2013‐00208)
`Paper 49 at 3 (IPR2013‐00206)
`Paper 46 at 3 (IPR2013‐00208)
`
`64
`
`
`
`Brantigan ’327
`
`Brantigan ’327 patent:
`
`Dr. Sachs:
`
`’327 Patent at 2:24‐25
`NUVASIVE 1006 at 5 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 37 (IPR2013‐00206); Paper 29 at 37 (IPR2013‐00208)
`
`Sachs Decl.
`WARSAW 2038 at ¶ 113 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 37 (IPR2013‐00206); Paper 29 at 37 (IPR2013‐00208)
`
`65
`
`
`
`Michelson ’247
`
`’247 Patent
`NUVASIVE 1008 at 1
`(IPR2013‐00206) (IPR2013‐00208);
`Paper 32 at 42 (IPR2013‐00206);
`Paper 29 at 42 (IPR2013‐00208)
`
`66
`
`
`
`Michelson ’247
`
`Michelson ’247:
`
`‘997 Patent:
`
`’247 Patent at 10:30‐36
`NUVASIVE 1008 at 12 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 54 (IPR2013‐00206); Paper 29 at 54 (IPR2013‐00208)
`
`’997 Patent at 4:4‐5; 3:26‐30
`NUVASIVE 1002 at 27; 23 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 46, 54 (IPR2013‐00206); Paper 29 at 46, 54 (IPR2013‐00208)
`
`67
`
`
`
`Berry et. al
`
`“A Morphometric Study of Human Lumbar and
`Selected Thoracic Vertebrae”
`
`McAfee Decl.
`NUVASIVE 1001 at 89 (IPR2013‐00206)
`NUVASIVE 1001 at 92 (IPR2013‐00208)
`Paper 32 at 44 (IPR2013‐00206)
`Paper 29 at 44 (IPR2013‐00208)
`
`68
`
`
`
`Michelson ’247
`
`Dr. McAfee Testimony:
`Q. And one of the risks associated with the posterior implantation of an
`implant is damage to the spinal nerves running up and down the column,
`right?
`A. Yes.
`Q. And another risk with a posterior to anterior insertion is that, as the
`implant is being pressed towards an anterior or in an anterior direction,
`one needs to be very careful about not interfering with the blood vessels
`that are situated to the front of the vertebra, correct?
`A. Yes.
`
`McAfee Dep at 43:8–18
`WARSAW 2039 at 14 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 42 (IPR2013‐00206)
`Paper 29 at 42 (IPR2013‐00208)
`
`69
`
`
`
`Michelson ’247
`
`Dr. McAfee Testimony:
`Q.
`Is there anything in the ‘247 Patent that actually states,
`and I’m, in writing here, that an implant inserted from an
`anterior to posterior direction should, in fact, span as
`much of the length from an anterior to posterior direction
`on the intervertebral space as possible?
`
`A. I agree the patent does not state that.
`
`McAfee Dep at 45:6–16
`WARSAW 2039 16 (IPR2013‐00206) (IPR2013‐00208)
`Paper 32 at 41 (IPR2013‐00206)
`Paper 29 at 41 (IPR2013‐00208)
`
`70
`
`
`
`NuVasive’s Combinations
`
`Jacobson, Leu, and Brantigan:
`Jacobson’s Instruments
`
`Leu
`
`Brantigan’s Implant
`
`Fig. 5
`NUVASIVE 1005 at 9 (IPR2013‐00206)
`(IPR2013‐00208)
`Paper 32 at 47 (IPR2013‐00206)
`Paper 29 at 47 (IPR2013‐00208)
`
`’374 Patent, Figs. 3 & 5
`NUVASIVE 1004 at 3 (IPR2013‐00206)
`(IPR2013‐00208)
`Paper 32 at 20, 26 (IPR2013‐00206)
`Paper 29 at 20 , 26 (IPR2013‐00208)
`
`’327 Patent, Figs. 11 & 12
`NUVASIVE 1006 at 4 (IPR2013‐00206)
`(IPR2013‐00208)
`Paper 32 at 28‐29 (IPR2013‐00206)
`
`71
`
`
`
`NuVasive’s Combinations
`
`Jacobson, Leu, and Michelson ’247:
`Jacobson’s Instruments
`Leu
`
`Michelson ’247’s Implants
`
`Fig. 5
`NUVASIVE 1005 at 9 (IPR2013‐00206)
`(IPR2013‐00208)
`Paper 32 at 47 (IPR2013‐00206)
`Paper 29 at 47 (IPR2013‐00208)
`
`’247 Patent, Fig. 4
`NUVASIVE 1008 at 5 (IPR2013‐00206)
`(IPR2013‐00208)
`Paper 11 at 44 (IPR2013‐00206)
`Paper 11 at 44 (IPR2013‐00208)
`
`’374 Patent, Figs. 3 & 5
`NUVASIVE 1004 at 3 (IPR2013‐00206)
`(IPR2013‐00208)
`Paper 32 at 20, 26 (IPR2013‐00206)
`Paper 29 at 20, 26 (IPR2013‐00208)
`
`72
`
`
`
`Case IPR2013-00208
`U.S. Patent No. 8,251,997
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of PATENT OWNER’S
`
`PRESENTATION was served in its entirety via electronic mail to APSI@fr.com
`
`(referencing Attorney Docket No. 13958-0112IP1); and cc'ing schaefer@fr.com
`
`and hawkins@fr.com:
`
`Stephen R. Schaefer
`
`Michael T. Hawkins
`
`3200 RBC Plaza
`
`3200 RBC Plaza
`
`60 South Sixth Street
`
`60 South Sixth Street
`
`Minneapolis, MN 55402
`
`Minneapolis, MN 55402
`
`
`
`
`
`
`Date of Service:
`
`June 5, 2014
`
`
`
`
`
`/Thomas H. Martin/
`Signature:
`
`
`Thomas H. Martin, Reg. No. 34,383
`
`
`
`
`
`
`
`
`
`
`